{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-001727","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2023-01-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.643666+00:00","generated_at":"2026-06-20T14:36:33.220926+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ADMA Q4 revs ~$49-50M (+89% YoY), FY22 revs ~$153-154M (+90%); guides FY23 revs $210M+, first positive EBITDA in H2 2023","bullets":["Q4 2022 preliminary revs ~$49-50M, up ~89% YoY; FY22 revs ~$153-154M, up ~90% over FY21.","FY2023 revenue guidance of $210M or more, representing ~40% YoY growth.","First-time positive EBITDA expected in second half of 2023.","Plans to open tenth plasma collection center and obtain FDA licensure for three additional centers in 2023.","Long-term financial targets reiterated; current trends tracking at upper bound of expectations."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-001727","json":"https://secwatch.observer/filing/0001140361-23-001727.json","markdown":"https://secwatch.observer/filing/0001140361-23-001727.md","text":"https://secwatch.observer/filing/0001140361-23-001727.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123001727/0001140361-23-001727-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123001727/brhc10046612_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T14:36:33.220926+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"05ddef87ab2c044fff2b8992a9479201f822b3e2","claim":"ADMA BIOLOGICS, INC. updated its 2023 guidance (initiated).","evidence_excerpt":"ADMA currently anticipates full year 2023 total revenues of $210 million or more.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123001727/0001140361-23-001727-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"b3e479b470b5c375e9af42cb1ffc8412411f91cf","claim":"ADMA BIOLOGICS, INC. reported fourth quarter and full year 2022 results: revenue preliminary, unaudited revenue for the fourth quarter ended December 31, 2022 to be approximately $49-50 million. Guidance reaffirmed.","evidence_excerpt":"ADMA Biologics, Inc. (the “Company”) issued a press release announcing its preliminary unaudited fourth quarter and full year 2022 revenues and providing 2023 financial guidance.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123001727/0001140361-23-001727-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year 2022"},{"label":"Revenue","value":"preliminary, unaudited revenue for the fourth quarter ended December 31, 2022 to be approximately $49-50 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}